免疫疗法
免疫检查点
癌症免疫疗法
癌症
免疫系统
PD-L1
单克隆抗体
癌细胞
封锁
小分子
癌症研究
癌症治疗
抗体
阻断抗体
T细胞
医学
免疫学
化学
内科学
生物化学
作者
Emma Baglini,Silvia Salerno,Elisabetta Barresi,Tiziano Marzo,Federico Da Settimo,Sabrina Taliani
出处
期刊:Mini-reviews in Medicinal Chemistry
[Bentham Science]
日期:2022-08-01
卷期号:22 (14): 1816-1827
被引量:3
标识
DOI:10.2174/1389557522666220217110925
摘要
Abstract: In 2018, James Allison and Tasuku Honjo received the Nobel Prize in physiology or medicine to discover tumor therapy by inhibition of negative immune regulation. Immunotherapy stimulates T-cells to fight cancer cells by blocking different immune checkpoint pathways. The interaction between programmed cell death 1 (PD-1) and its ligand PD-L1 (Programmed cell death ligand 1) is one of the main pathways. Of note, interfering with this pathway is already exploited in clinical cancer therapy, demonstrating that it is one of the key factors involved in the immune escape mechanism of cancer. The development of monoclonal antibodies (mAbs) that possess the ability to inhibit the interactions between PD-1/PD-L1 has radically made the difference in cancer immunotherapy. Yet, due to the many drawbacks of this therapy, the research shifted its efforts towards the development of novel small molecules. This may constitute hope and an arduous challenge in fighting cancer. This paper reviews the recent primary literature concerning the development of novel small molecules able to block the interaction between PD-1 and its ligand PD-L1.
科研通智能强力驱动
Strongly Powered by AbleSci AI